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Tumor-released extracellular vesicles (EVs) contain tumor-specific cargo distinguishing them from healthy EVs, and
making them eligible as circulating biomarkers. Glypican 1 (GPC1)-positive exosome relevance as liquid biopsy
elements is still debated. We carried out a prospective study to quantify GPC1-positive exosomes in sera from
pancreatic ductal adenocarcinoma (PDAC) patients undergoing up-front surgery, as compared to controls including
patientswithoutcancerhistoryandpatientsdisplayingpancreaticpreneoplasic lesions.Serawereenriched inEVs,and
exosomes were pulled down with anti-CD63 coupled magnetic beads. GPC1-positive bead percentages determined
by flow cytometry were significantly higher in PDAC than in the control group. Diagnosis accuracy reached 78%
(sensitivity 64% and specificity 90%), when results from peripheral and portal blood were combined. In association
with echo-guided-ultrasound-fine-needle-aspiration (EUS-FNA) negative predictive value was 80% as compared to
33%forEUS-FNAonly. This approach is clinically relevant as a companion test to thealreadyavailablediagnostic tools,
since patients with GPC1-positive exosomes in peripheral blood showed decreased tumor free survival.
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Pancreatic ductal adenocarcinoma (PDAC) is discovered at advanced
stages because its clinical presentation is preceded by non-specific
symptoms. The only curative treatment is surgery but only 20% of
the patients are eligible for tumor resection [1,2]. Several diagnostic
tools such as imaging are needed, making diagnosis long and costly
[3,4]. PDAC management is complicated by the fact that the onset of
neo-adjuvant or palliative therapies depends on the required
histological proof of the presence of the tumor. This proof, routinely
obtained by conventional biopsies, is risky for the patients. For
example, endoscopic ultrasound-guided fine needle aspiration
(EUS-FNA) may result in cancer cell dissemination along the needle
track, may provoke pancreatitis, and its predictive negative value is
low [3]. When EUS-FNA is negative, the procedure is repeated
leading to delayed patient management, which worsens the prognosis[5]. The CA19-9 (Carbohydrate Antigen) or CEA (Carcinoembryo-
nic Antigen) plasma biomarkers have poor sensitivity and specificity
and are not recommended for PDAC diagnosis [6e8]. Finally, even
when resection is possible and complete, a high percentage of patients
develop metastatic disease, without possible identification before
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diagnostic, predictive and prognostic tools for PDAC.
In 2015, a major advance was published by Melo et al. identifying
PDAC by quantifying circulating tumor-specific exosomes enriched
in the membrane protein heparan sulfate proteoglycan glypican 1
(GPC1) [11]. GPC1 is overexpressed in PDAC primary tumors [12]
and supports tumor cell proliferation and migration [13]. Moreover,
heparan sulfate proteoglycans, including GPC1 are involved and
remain in exosome internalization [14]. GPC1 was found membrane
bound to exosomes isolated from several cancer cell lines where it was
also up-regulated as compared to healthy fibroblasts [11]. Based on
this observation, a flow-cytometry test distinguished perfectly PDAC
over healthy donors or patients with benign pancreatic diseases in
exosome-enriched sera. Since this proof of principle, studies trying to
confirm this crucial advance have reached various degrees of
validation. In 2017, exosomal GPC1 quantified by liquid chromato-
graphy-mass spectrometry/mass spectrometry (LCeMS/MS), using a
GPC1 specific peptide, did not identify PDAC patients over controls
(healthy donors or chronic pancreatitis (CP), [15]). Instead, a
5-microRNA signature with high miR-10b, -21, -30c, and 181a and
low let7a differentiated PDACs from controls. In the same way, a
signature of 5 proteins (EGFR, EpCAM, MUC1, HER2, GPC1 and
WNT2), found by EV (extracellular vesicle)-based protein marker
profiling identified PDAC patients with a sensitivity of 86% and a
specificity of 81% [16]. In this report, EV-GPC1 used alone did not
distinguish PDAC patients from controls. In 2018, alternating
current electrokinetic (ACE) microarray chip, capturing exosomes
directly from plasma, followed by immunofluorescent detection and
quantification of CD63 and GPC1 did identify PDAC over healthy
patients [17]. This is the only independent study confirming the
possibility to diagnose PDAC patients by quantifying CD63high/
GPC1high exosomes. Thus, according to conflicting results in
published data, a key question to answer is whether reported findings
on GPC1-positive exosomes identifying PDAC can be validated
independently in early stage patients.
We used a prospective cohort of patients who underwent up-front
surgery without neo-adjuvant treatment for localized PDAC, because
they are the population of patients for whom rapidity in diagnostic is
crucial to avoid delay, and lower cancer progression risk. We pulled
down GPC1-positive exosomes from sera from cancer patients and
non-cancer controls, with anti-CD63 coupled magnetic beads and
quantified them by flow cytometry. Importantly, we tested the
hypothesis that GPC1-positive exosomes might be more numerous in
portal blood drained from the primary tumor. We assessed the
diagnostic accuracy of this method as compared to CA19-9
quantification, endoscopy ultrasound guided fine needle aspiration
(EUS-FNA) tumor cell identification and KRAS circulating tumor
DNA amplification.
Materials and Methods
Patients Demographics
Patients eligible for pancreatic surgery with suspicion of pancreatic
cancer or IPMN (intraductal papillary and mucinous neoplasm) with
worrisome features as determined by CT-scan (computerized tomo-
graphy scanner) and or MRI (magnetic resonance imaging) without
metastasis were enrolled at the department of hepatobiliary surgery of
Bordeaux university hospital between February and November 2017.
This prospective study was conducted according to the Declaration ofHelsinki, the French rules (Law for Bioethics November 2016) and the
recommendations of CNIL (Comite National Informatique et Liberte),
and was approved by an Institutional Review Board. The biological
collectionwas declared to and approvedby the “comite de protection des
personnes sud ouest outremer” under the number 2016-A00431-50
and the database was registered in Clinical Trials under the number:
NCT03032913. Informed consent was obtained from patients and
before surgery. Patients did not receive neoadjuvant therapy. A control
group enrolled patients, with informed consent, undergoing surgery for
benign pathologies, and with no history of cancer. Patient follow-up,
completed until December 1, 2018, evaluated survival and disease
recurrence.
Blood Sampling
Two samples of 7.5 ml of blood were collected from the portal vein
in BD vacutainer collection tubes without additives (SST tubes,
Becton Dickinson, Le Pont de Claix, France), after laparotomy, before
manipulation of the tumor. Two samples of 7.5 ml were collected
during surgery in the median cephalic vein in BD vacutainer collection
tubes without additives. A sample of 7.5ml inBDvacutainer collection
tube containing EDTA was collected for complete blood count, to
determine neutrophil over leukocyte ratio in the patient group (DXH
automated counter, Beckman Coulter, Villepinte, France). Median
cephalic vein was punctured in the control group, to collect sample in
vacutainer collection tubes without additives. Tubes were centrifuged
quickly at 2000 g for 15minutes to collect sera. Sera from patients were
immediately used to determine CA19-9 concentration (Architect
automated instrument, Abbott). Then serawere frozen at80 Cuntil
they were further processed. In addition, one tube (Cell free DNA
collection tube©, Roche,Meylan, France) was collected in a peripheral
vein for all patients and controls, and also in the portal vein for IPMN
and PDAC groups for ctDNA analysis.
Exosome Isolation and Flow Cytometry
Sera were enriched in extracellular vesicles (EVs) using the Total
Exosome Isolation kit (Thermofisher, Courtaboeuf, France), accord-
ing to the manufacturer's instructions. Briefly, serum samples stored
at80 Cwere thawed on ice and centrifuged at 2000 g for 30minutes
to remove cells and debris. Sera supernatants were incubated for 30
minutes with Total Exosome Isolation reagent at 4 C and centrifuged
for 10 minutes at 10,000 g. EV-enriched pellets were resuspended in
Phosphate Buffered Saline (PBS), and stored at 20 C. The
Exosome-HumanCD63 Isolation/Detection Reagent (Thermofisher)
was used to pull down sera exosomes. Magnetic bead-coupled
exosomes were stained with anti-CD63-FITC (Biolegend, London,
UK) to validate exosome isolation. Flow cytometry analysis confirmed
that 98 to 99% of the beads were CD63-positive (not shown).
Anti-CD9-PE antibody (Biolegend) and anti-GPC1 primary antibody
(PIPA528055, Thermofisher) revealed with Alexa Fluor 647 donkey
anti rabbit IgG (Biolegend) were used together. All staining steps and
washes were carried out in PBS1X/ BSA 0.1%. Samples were examined
on a BD FACSCANTO II apparatus using unstained beads and beads
stained with isotype controls (PE mouse IgG1 Kappa isotype control
clone MOPC-21 (Biolegend) and rabbit igG isotype control Alexa
Fluor 647 conjugate (OZYME,Montigny-le-Bretonneux, France)) to
setup quantification areas on dot plots.Data were collected on FSC and
SSC linear parameters (645 V and 520 V, respectively) and on a
logarithmic scale for Alexa 647 and PE (455 V and 400 V,
respectively). Data were analyzed with BD FACS Diva software (BD
Table 1. Clinical and histological features of the cohort
Variables PDAC group (n¼ 22)
N (%)
Control group (n¼ 28)
N (%)
Age, y, (median; range) 68.8 (69.5; 57-81) 58.3 (61;22-73)
Male gender, n (%) 13 (59) 8 (28)
Serum CA19-9 (n¼ 19 PDAC group)
Normal
Elevated 16 (84) 23 (82)
3 (16) 5 (IPMN) (18)
NLR mean (med; range) 7.19 (3.7; 0.69-21)
EUS-FNA Total n¼ 18
Positive n¼ 8
Negative n¼ 10
Pathology: Macroscopic
Tumor size (mm) mean (med; range) 31 (30; 11-50)
Tumor stage (mean) Stage 1a: 1 (5)
Stage 1b: 4 (18)
Stage 2b: 11 (50)
Stage 3: 6 (59.2)
Glandular Differentiation (%) Well 3 (13.6)
Moderately 11 (50)
Poorly 8 (36.4)
KRAS status all primary tumors were positive for
KRAS:
Mutant allele frequency mean (med; range) 2 6 . 1 5
(17.45;0.35-77.6)
IPMN (n¼ 8) are included in the control group. Med, median; PDAC, pancreatic ductal
adenocarcinoma; IPMN, intraductal papillary and mucinous neoplasm; EUS-FNA endoscopic
ultrasound-guided fine needle aspiration; NLR, neutrophil to lymphocyte ratio; med, median; Note
that CA19-9 dosages for 3 PDAC patients were uninterpretable because of jaundice.
Suspicion PDAC eligible for up-front surgery 
n=32
IPMN n=8 
PDAC study group
n=22 
11 Cholecystectomy
3 Bariatric procedure
2 hernia surgery
2 chronic pancreatitis
2 Functional pelvic surgery
Control group
n=28
Exclusion 
Metastatic n=2
Figure 1. Patient selection criteria.PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary and mucinous neoplasm.
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in independent experiments.
Western Blot Analysis
Proteins from vesicle-enriched sera with Total Exosome Isolation
kit, were extracted as already described [18]. We used the same
primary antibodies as in flow cytometry analysis. Densitometry
quantification was carried out with Image J 1.52a software [19].
ctDNA Quantification
Plasmas were collected in Cell free DNA collection tube and were
subjected to DNA extraction (RSC ccfDNA plasma kit, Maxwell
(Promega, Charbonnieres-les-Bains, France)). Tissue DNA was
extracted from FFPE specimens using Maxwell® RSC DNA FFPE
Kit (Promega) according to the manufacturer's instructions. KRAS
mutant alleles were detected by droplet digital PCR (ddPCR) with the
KRAS G12/G13 Screening Kit (Biorad, Marne la Coquette, France).
Statistics
Qualitative and quantitative data were analyzed with usual statistic
tools (including Student's-test, Chi-Square and Fisher exact tests)
using GraphPad-Instat and GraphPad-Prism 8.0 software (GraphPad
Software Inc., San Diego, CA, USA). The Spearman correlation
coefficient was used to assess the correlation between different
variables. Group differences were tested using the nonparametric
Wilcoxon-ManneWhitney test for two groups. Receiver operating
curves (ROC) were obtained to describe the accuracy of detecting
cancer. The cutoff points were selected using Youden's index, which
maximizes the sum of sensitivity and specificity. ROCs and Youden's
index calculation were performed using SAS software (version 9.4,
SAS institute, Cary, NC, USA).
Results
Patient Characteristics
From February to November 2017, 72 patients underwent surgery
for PDAC of which 32 had an up-front surgery for presumed PDAC
without neo-adjuvant therapy (Figure 1). Among them, two patientswere excluded because metastatic disease was discovered during
surgery, and 8 patients were excluded from the cancer group and
switched to the control group after definitive pathology analysis,
because of non-invasive intraductal papillary mucinous neoplasm
(IPMN) diagnostic. Thus, control group included 20 control patients
operated in our surgical unit without neoplasia and without a history
of cancer (including two chronic pancreatitis who underwent surgery
for symptomatic reasons) and 8 IPMN (Figure 1). Demographic and
clinicopathological characteristics are shown in Table 1. The groups
were similar according to all clinical features (Table 1). Mean tumor
1398 GPC1 diagnosis pancreatic ductal adenocarcinoma Buscail et al. Translational Oncology Vol. 12, No. 11, 2019size was 31 mm. All tumors were resectable without vascular
involvement (i.e. superior mesenteric artery or superior mesenteric or
portal vein).
GPC1 Positive Exosomes in Peripheral Blood
We tested the presence of GPC1, CD9 and CD63 proteins
extracted from vesicle-enriched sera of patients and controls. Western
blot analysis found expected signals for the exosomes markers CD63
and CD9 and GPC1 (Fig. 2). Densitometry analysis showed that
GPC1 expression levels were similar in PDAC and control groups. By
contrast CD63 signals were higher in the PDAC group by almost
twofold (P¼ .04, n¼ 4).
Previous data reported that PDAC exosomes overexpressed both
CD63 and GPC1 as measured by alternative current electrokinetic
(ACE) [17]. In their working model the authors used both
biomarkers to discriminate PDACs from healthy donors. Our total
EV GPC1 levels were similar in both groups by western blot, so we
hypothesized that pooling down CD63-positive EVs followed by
GPC1 detection would distinguish cancer patients from non-cancer
controls. First, anti-CD63 magnetic beads were used to obtain
CD63-positive exosomes from peripheral blood. As expected, they
were positive for the exosome specific CD9 marker with no difference
between PDAC and control groups, including healthy volunteers and
patients with IPMNs (P¼ .5, Figure 3, A and B, Table 2).
Interestingly, mean percentages of GPC1-positive beads were
significantly higher in the PDAC group as compared to non-cancer
patients (23.7± 7.31, n¼ 22 and 5.7± 3.88, n¼ 20, respectively,
P¼ .04 by unpaired Student's t test, Figure 3, A and C, Table 2). The
IPMN group was not significantly different from both other groups
(9.71± 7.50, n¼ 8, P > .05 by unpaired Student's t test). The
positivity threshold for GPC1 exosomes calculated using the Youden
index was 5%. Fifty percent of the patients were above this threshold.
GPC1 Positive Exosomes in Portal Blood
We hypothesized that circulating tumor exosomes could be more
numerous in a blood sample drawn from the portal vein, near the
tumor, as compared to peripheral blood drawn from the median
cephalic vein. Portal samples were obtained only in the operatedCD9
(24-27 kDa) 26
CD63
(30-60 kDa) 55
43
PDAC
72
GPC1
(62k Da + 
glycosylated 
forms)
CONTROLS kDa
55
130
1±0.090.88±0.4
1±0.942.35±0.47
NS
p=0.04
Figure 2. GPC1 is present in patient and control EV-enriched
sera.Proteins extracted from patient and control sera were
analyzed by western blotting for the presence of CD63 and CD9
exosome markers and for GPC1 proteins. Protein sizes of
marker are indicated by arrow heads in kDa. A Student's t test
was used to compare densitometry values of CD63 and GPC1
band intensities over CD9 signal.patients. GPC1-positive bead percentages were not significantly
different in peripheral and portal samples (16.33 ± 6.19, n¼ 22 and
7.3± 6.31, n¼ 8, respectively, P¼ .42, Figure 3D), even if they
tended to be lower in the portal samples. Next, as we had both portal
and peripheral blood samples of the 31 patients we assessed whether
GPC1-positive bead percentages matched between samples
(Figure 3E). Three patients presented discordant results, but overall,
percentages were correlated with Pearson's test (r¼ 0.59, P¼ .037).Diagnostic Performance
Diagnostic performance was evaluated by determining accuracy,
sensitivity and specificity (Table 3). Overall, diagnosis accuracy of
GPC1-positive exosomes was better in peripheral blood than in portal
blood. A total of 63% (14 out of 22) of patients were detected for
GPC1 positive exosomes in portal and/or peripheral blood. Both
sampling sites showed better performance than CA19-9. EUS-FNA
carried strong specificity, but poor negative predictive value, as
expected. Interestingly, combining all three diagnostic tools led to
high sensitivity and specificity (82% and 86%, respectively), and
highest diagnosis accuracy (84%, Table 3). ROC curves showed that
GPC1-positive exosomes in peripheral blood displayed higher area
under the curve (AUC) than CA19-9 in peripheral blood (Figure 4).ctDNA Detection
All patients and controls were negative for circulating KRAS
mutant DNA in peripheral or portal blood, whereas both our
metastatic patients had detectable KRAS mutant alleles (data not
shown and mutant allelic frequency in peripheral blood: 1.6% and
0.6%; in portal blood 0.41%and 0.4%). Thus, ctDNA did not
distinguish PDAC patients from controls.
Importantly, all primary tumors were KRAS mutant with a mean
mutant allele frequency of 26.15 (Table 1).Correlation of Exosome Levels to Clinicohistopathologic Risk
Factors and Prognostic Values
The median follow-up was 18 months (range 2-23). All data were
included until December 2018. A low positive correlation between
the percentage of GPC1-positive exosomes in peripheral blood
(Figure 5A), but not in portal blood (Figure 5B) and the tumor size
was found (Pearson's test r¼ 0.39, Figure 5A), with a p value close to
statistical significance (P¼ .07). Exosome rate did not correlate with
other histolopathological parameters, including tumor stage, the
number of invaded lymph nodes and carcinoma differentiation.
Despite the short follow-up period (median 554 days; mean 532 days;
range 74-718 days) and the small size of the cohort, we analyzed the
exosome results in the context of the clinical follow-up. Among the 22
patients, 14 developed tumor recurrences (64%), including meta-
static relapses in the liver and other organs. Four patients died (18%).
KaplaneMeier analysis indicated that overall survival did not
correlate patients with GPC1 positive exosome in peripheral blood
above the threshold (Figure 5C) but they relapsed sooner than
patients with GPC1-positive exosomes below the threshold (P¼ .01,
Figure 5D).
Thus, the diagnostic value of GPC1 positive exosomes is superior
when combining portal and peripheral analyses, but the prognostic
value is only retained for GPC1 positive exosomes in the peripheral
blood.
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Table 2. Numeric results of exosome quantification in PDAC patients and control group.
Sample PDAC group Control group
Portal samples (n) 22 8 (IPMN)
Peripheral samples (n) 22 28
CD9 positive (n (%)) peripheral blood 22 (100%) 28 (100%)
CD9 positive beads rate peripheral blood mean (med; range) 31.4 (19.45;1-87.1) 42.7 (41.2;1-90.3)
CD9 positive beads (n (%)) portal blood 22 (100%) 8 (100%)
CD9 positive beads rate portal blood mean (med; range) 22.5 (12.45;1-94) 36.4 (40;1-91.8)
GPC1 positive (n (%)) peripheral blood 11 (50%) 3 (10.7%)
GPC1 positive beads rate peripheral blood mean (med; range) 23.7 (3.45;1-96.5) -IPMN:9.71 (2.65;0.3-62.1)
-Control (without-IPMN n¼ 20): 5.7 (0.7;0-77.3)
-Control (with IPMN n¼ 28):
7.02 (1.35;0-77.3)
GPC1 positive (n (%)) portal blood 10 (46%) 1 (12%)
GPC1 positive beads rate portal blood mean (med; range) 16.33 (3.6;1-92.6) 7.3 (0.7;0.6-51.4)
GPC1 positive portal and peripheral n (%) 14 (63%) 3 (10.7%)
med, median; PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary and mucinous neoplasm.
Table 3. Diagnosis values of GPC1 positive exosomes, CA19-9 and EUS-FNA
Test Sensitivity (95% CI) Specificity (95%CI) Positive predictive value
(95%CI)
Negative predictive
Value (95%CI)
Diagnosis accuracy (95%CI)
EVs GPC1 portal vein 46
(27-66)
88
(53-99)
91
(63-99)
36
(20-59)
57
(50-64)
EVs GPC1 peripheral vein 50
(31-70)
90
(77-99)
79
(58-98)
70
(54-82)
72
(65-78)
*EVs GPC1 peripheral and/or portal vein 64
(43-81)
90
(73-97)
83
(59-94)
76
(59-88)
78
(72-83)
CA19-9 37
(19-59)
87
(72-95)
63
(36-85)
69
(54-82)
68
(61-74)
EUS FNA (n¼ 18; PDAC n¼ 15; IPMN n¼ 3) 60
(36-81)
100
(31-99)
100
(60–99)
33
(13-65)
66
(59-73)
*EVs GPC1 and CA19-9 72
(52-87)
93
(78-99)
89
(68-99)
81
(65-92)
84
(78-89)
CA19-9 and EUS-FNA 50
(31-70)
92
(78-99)
86
(58-98)
70
(55-83)
74
(67-80)
*EVs GPC1 and EUS FNA 73
(52-87)
86
(69-95)
80
(59-92)
80
(63-91)
80
(74e85)
*EVs GPC1þCA19-9þ EUS FNA 82
(62-93)
86
(69-95)
82
(62-93)
86
(69-95)
84
(78-89)
PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary and mucinous neoplasm; EUS-FNA endoscopic ultrasound-guided fine needle aspiration. *EVs GPC1, quantification in peripheral
and portal vein.
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Tumor EVs carry sufficient information to control the activity of
recipient cells, whether they are tumoral [20] or healthy [21], leading
to responses supporting tumor growth or dissemination. Thus, they
seem to be very relevant material as circulating tumor biomarkers
carriers, such as nucleic acids, proteins or lipids. In this way, the
identification of GPC1-positive exosomes as highly specific and
sensitive biomarkers to diagnose PDAC was very exciting [11]. A few
reports have been published to test this potentially powerful
diagnostic tool. Our study aimed at confirming this breakthrough
finding in a group of PDAC patients eligible for up-front surgery,
considered detected early in the course of the disease [22]. Moreover,Figure 3. GPC1-positive exosomes partially identify PDAC patie
quantification of positive exosomes for the exosome specific ma
detection according to physical criteria (size, FSC and granularity, S
stain (medium top panel) and PEmouse IgG1 Kappa isotype (right
a PDAC patient and lower three panels show representative resu
each dot plot. GPC1/CD9 results correspond to % of GPC1-positive
plotted for each group of participants, for CD9-positive exosome c
peripheral blood (C), GPC1-positive exosome counts in portal bloo
blood versus portal blood has been plotted in (E). The dashed linesas for circulating tumor cells, it is possible that such patients might
release less tumor-related elements in the blood circulation as the
disease is less advanced [23], making their detection even more
challenging.
First, we detected GPC1 protein at the expected size in
vesicle-enriched sera by western-blot and found no difference in
signal intensity between patients and healthy controls. We tested very
few samples (n¼ 4 in each group) as the main aim of our work was to
quantify GPC1-positive exosomes. Increasing the number of samples
might identify significant differences in both groups as published for
serum GPC1 levels measured by ELISA [24]. This latter work
however, found that serum GPC1 was inferior to CA19-9 in terms ofnts.(A) Representative dot plots of PDAC and controls for the
rker CD9, and the GPC1 protein. Top three panels show bead
SC, left panel), rabbit igG isotype control Alexa Fluor 647 control
top panel). Three medium panels show representative results for
lts for a control. Percentages of stained beads are indicated in
beads within the CD9-positive population. Individual results are
ounts in peripheral blood (B), GPC1-positive exosome counts in
d (D). Correlation of GPC1-positive exosome counts in peripheral
delineate the positivity threshold. Ns: not significant. *: P< .05.
Figure 4. ROC curves for GPC1-positive exosomes and CA19e9.The ROC curves were built with data obtained from peripheral blood
for markers used alone (GPC1-positive exosome (green curve) and CA 19e9(pink curve)), or for GPC1-positive exosome measured in
portalblood (browncurve), or for combinedGPC1-positiveexosomesmeasured inportal andperipheralblood (graycurve); foreachpair,
we took the lowest%GPC1þ exosomes of PDAC and the highest lowest %GPC1þ exosomes of controls. AUC, area under the curve.
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PDAC.
The first publication proposing GPC1-positive exosomes for
identifying PDAC reported 100% sensitivity and 100% specificity
[11]. Yang et al. [16] described an EV protein signature (EGFR,
EpCAM, MUC1, HER2, GPC1 and WNT2), by measuring
antibody-linked fluorescence intensity of ultracentrifuged plasma
EVs, identifying PDAC with a diagnostic accuracy of 84%, aA
C
Figure 5. Analysis of GPC1-positive exosome quantification acco
between positive GPC1 exosomes in peripheral blood and tumor s
portal blood and tumor size. (C) Overall survival according to pres
free survival according to presence of GPC1-positive exosome
exosomes ¼ 5% as determined by Youden's index. r, Pearson cosensitivity of 86% and a specificity of 81%. Detecting GPC1 alone
showed a lower diagnosis accuracy of 67%, a sensitivity of 82% and a
specificity of 52% (n¼ 43). We found a similar accuracy of 72% but
a lower sensitivity (50%) and a higher specificity (90%). In addition,
Lai et al. [15] did not report diagnostic performance for
GPC1-positive exosome but did not find significant difference in
levels of GPC1 protein in exosomes from PDAC versus controls, in
small groups (n¼ 3 and n¼ 6, respectively), and using LCeMS/MS,B
D
rding to clinical and pathological criteria.(A) Pearson correlation
ize. (B) Pearson correlation between positive GPC1 exosomes in
ence of GPC1-positive exosomes in peripheral blood. (D) Tumor
s in peripheral blood. Positivity threshold for GPC1 positive
rrelation coefficient.
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Frampton et al. were unable to distinguish PDAC from benign
pancreatic disease using ultracentrifuged plasma and ELISA [25]. A
recent publication identified PDAC patients with alternating current
electrokinetic (ACE) microarray chip, capturing nanoscale objects,
including exosomes, directly from plasma, followed by immuno-
fluorescent detection and quantification of CD63 and GPC1.
Although high sensitivity and specificity (99% and 82%, respectively)
were achieved, false-positive and false-negative results were obtained
[17]. Even more recently, enumeration of GPC1-positive EVs, solely
or in conjunction with Glycoprotein 2, did not distinguish PDAC
from benign pancreatic diseases, using direct EVs detection with a
nanoscale flow cytometer and an anti-GPC1 antibody different from
Melo's [26]. Thus, GPC1 positive exosome quantification showed
various results in terms of diagnostic accuracy. The discrepancies
might originate from different technical approaches to measure
exosome-GPC1 levels. For example, with our approach, it is possible
that the reagent used to isolate EVs might interfere with GPC1
immunodetection on the magnetic beads. We did test ultracentrifu-
gation followed by latex beads coupling and did not distinguish
PDAC from controls (n¼ 6 PDACs n¼ 19 controls, not shown).
Thus, as the first enrichment step in EVs, we used a density-based
separation kit coupled to magnetic beads decorated with anti-CD63,
limiting the analysis to the exosome population [27]. CD9 positivity
was various among patients. This could be explained by the variety of
EVs presenting the CD63 tetraspanin at their surface, such as non
exosomal microvesicles [28]. We used the same antibody as Melo,
because this parameter seemed crucial in reproducing their results.
This approach improved PDAC patient identification. Our results are
similar to already published results [15,16,25].
As blood from portal vein is enriched in circulating tumor cells
[29,30], we hypothesized that GPC1-positive EVs were more
numerous in portal samples. To our knowledge, this series is the
first testing GPC1-EVs in portal vein samples. In fact, we found that
although not significantly different, GPC1-positive EVs tended to be
less concentrated in portal blood as compared to peripheral blood.
Sensitivity and specificity were similar but positive predictive value
was higher (91% vs 79%) suggesting that that portal sample can
improve PDAC identification. Moreover, combined results found
better AUC in ROC curves (Figure 4). In the same way, combining
peripheral and portal blood analysis led to better diagnostic
performance (Table 3). Noticeably, this approach is valid since portal
blood sampling is feasible. Indeed, authors reported sampling of
portal vein for 18 patients during EUS FNA for circulating tumor
cells enrichment [31].
As already published, ctDNA did not identify early stage PDAC as
we only detected our two metastatic patients [23]. Recently, it was
reported that quantifying tumor DNA in exosome might not be more
useful since only 25% to 29% of PDAC patient had KRAS or TP53
mutant DNA in exosomes [16].
Our cohort is prospective and homogenous since composed of
patients all eligible for up-front surgery, which was confirmed by
histopathological analysis. Previous studies identifying circulating
tumor elements in PDAC included mainly advanced stages or
metastatic patients. At this stage of the disease, our control group is
interesting because it consists of heterogeneous pathologies, two
patients with chronic pancreatitis and eight patients with pre-neo-
plastic cystic lesions. Nevertheless, the cohort presents limits. In
particular, the number of patients is small and conclusions need to bevalidated in a larger prospective cohort. This is especially true when
we analyzed correlations between exosomes levels and clinicohisto-
pathologic data. Pearson correlation coefficient showed a low positive
correlation between exosomes levels and tumor size and P value was
0.07. This is in accordance with a recent study showing that patients
with high GPC1 in circulating exosomes had larger tumors [12,25].It
is probable that increasing cohort size would reach statistical
significance. Importantly, as previously suggested, our results even
on a small cohort show that GPC1-positive exosomes carry prognostic
value for disease relapse [12,24]. Determining the levels of
GPC1-positive exosomes might help setting up neoadjuvant strategy
for these patients [32].
Traditional tools for the diagnosis of PDAC include CA19-9 and
histologic proof currently obtained by EUS-FNA [10]. Patients with
early-stage disease are more difficult to diagnose by EUS-FNA.
Cytopathological specimens, may reach high sensitivity (75%e98%),
specificity (71%e100%), but are not devoid of post-procedure
morbidity, especially pancreatitis. The presence of pancreatitis
decreases sensitivity to 74% as compared to 91% with normal
surrounding pancreatic parenchyma. Current data show that the
negative predictive value of EUS-FNA actually ranks between 33 and
85% [3,10,33]. This is probably due to the histological nature of the
tumor, rich in fibrosis and often poor in tumor cells. Our series
presented the most difficult diagnostic conditions since patients were
all at an early stage with small lesions. Moreover, PDAC management
tends now to perform neoadjuvant therapy even for patients eligible
for up-front surgery. So, the low negative predictive value of
EUS-FNA is becoming problematic [5]. Quantifying GPC1 positive
EVs in the peripheral and/or the portal blood as a companion test
might improve the diagnostic leading to a negative predictive value of
80% (as compared to 33% for EUS-FNA alone).
CA19-9 had sensitivity and specificity as low as 70% and 68%
respectively, which is in agreement to recommendations to not use it
routinely for diagnosis [7,8]. In the same way, CA19-9 is not a good
prognostic marker for early stages [9]. Accordingly, we found a very
low sensitivity (37%) and a specificity of 87%. Interestingly however,
combining all three diagnostic tools, i.e. GPC1-positive EVs, CA19-9
and EUS-FNA improved all diagnostic performance parameters
(Table 3), and displayed the best diagnosis accuracy (84%).
Consequently, it would be very interesting to test in a larger cohort
a patient early management strategy including GPC1-positive
exosome quantification. Indeed, liquid biopsy is a very low risk
procedure and additional cost is manageable.
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